Apyx Medical (APYX) Liabilities and Shareholders Equity (2010 - 2026)

Apyx Medical (APYX) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $61.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 4.96% year-over-year to $61.1 million; the trailing twelve-month figure through Jun 2026 stood at $248.3 million (up 1.8% YoY), and the FY2025 full-year result was $66.8 million, up 3.08% from the prior year.
• Liabilities and Shareholders Equity fell to $61.1 million in Q2 2026 per APYX's latest filing, from $63.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $79.2 million in Q4 2023 and bottomed at $51.8 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $62.0 million across 5 years, with a median of $60.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity decreased 24.66% in 2022, then jumped 53.05% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $51.8 million in 2022, then surged by 53.05% to $79.2 million in 2023, then declined by 18.17% to $64.8 million in 2024, then gained by 3.08% to $66.8 million in 2025, then retreated by 8.63% to $61.1 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $61.1 million, $63.0 million, and $66.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.